The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis

International Journal of Neuroscience

Volumn 126, Issue 8, 2016, Pages 700-706

  Demirci, Seden ^a   Demirci, Serpil ^a   Kutluhan, Suleyman ^a   Koyuncuoglu, Hasan Rifat ^a   Yurekli, Vedat Ali ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

multiple sclerosis; neutrophil to lymphocyte ratio; prognosis; relapse

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUTROPHIL LYMPHOCYTE RATIO; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; BLOOD; LYMPHOCYTE; LYMPHOCYTE COUNT; MIDDLE AGED; NEUTROPHIL; PATHOPHYSIOLOGY;

ADULT; BIOMARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUTROPHILS; PROGNOSIS;

EID: 84938316818     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2015.1050492     Document Type: Article

References (39)

1. A.Compston, A.Coles. Multiple sclerosis. Lancet 2008;372:1502–17.
2. S.Sawcer, G.Hellenthal, M.Pirinen, Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214–9.
3. V.K.Harris, V.A.Sadiq. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 2009;13(4):225–44.
4. E.Meinl, M.Krumbholz, R.Hohlfeld. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006;59:880–92.
5. Z.Matejčíková, J.Mareš, H.Přikrylová Vranová, Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study. J Neural Transm 2014. doi:10.1007/s00702-014-1244-9.
6. F.Imtiaz, K.Shafique, S.S.Mirza, Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med 2012;5(1):2.
7. M.Naegele, K.Tillack, S.Reinhardt, Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol 2012;242(1-2):60–71.
8. K.Steinbach, M.Piedavent, S.Bauer, Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs. J Immunol 2013;191(9):4531–9.
9. K.Tillack, M.Naegele, C.Haueis, Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients. J Neuroimmunol 2013;261(1-2):108–19.
10. E.Granieri, I.Casetta, M.R.Tola, P.Ferrante. Multiple sclerosis: infectious hypothesis. Neurol Sci 2001;22:179–85.
11. S.R.McColl, M.A.Staykova, A.Wozniak, Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J Immunol 1998;161(11):6421–6.
12. M.Khademi, I.Kockum, M.L.Andersson, Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011;17(3):335–43.
13. A.J.Fowler, R.A.Agha. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography – the growing versatility of NLR. Atherosclerosis 2013;228:44–5.
14. N.Dirican, C.Anar, S.Kaya, The clinical significance of hematologic parameters in patients with sarcoidosis. Clin Respir J 2014 doi:10.1111/crj.12178.
15. B.B.Sen, E.N.Rifaioglu, O.Ekiz, Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol 2013;33(3):223–7.
16. G.U.Okyay, S.Inal, K.Onec, Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Ren Fail 2013;35:29–36.
17. A.Dirican, N.Ekinci, A.Avci, The effects of hematological parameters and tumor-infiltrating lymphocytes on prognosis in patients with gastric cancer. Cancer Biomark 2013;13(1):11–20.
18. S.Tokgoz, M.Kayrak, Z.Akpinar, Neutrophil lymphocyte ratio as a predictor of stroke. J Stroke Cerebrovasc Dis 2013;22:1169–74.
19. Y.Arbel, A.Finkelstein, A.Halkin, Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis 2012;225:456–60.
20. G.Ertas¸, O.Sönmez, M.Turfan, Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation. J Neurol Sci 2013;324:49–52.
21. M.E.Kuyumcu, Y.Yesil, Z.A.Oztürk, The evaluation of neutrophil-lymphocyte ratio in Alzheimer's disease. Dement Geriatr Cogn Disord 2012;34:69–74.
22. S.Gokhan, A.Ozhasenekler, H.Mansur Durgun, Neutrophil lymphocyte ratios in stroke subtypes and transient ischemic attack. Eur Rev Med Pharmacol Sci 2013;17:653–7.
23. E.Akıl, A.Bulut, I.Kaplan, The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson's disease. Neurol Sci 2014. doi:10.1007/s10072-014-1976-1.
24. T.B.Martins, J.W.Rose, T.D.Jaskowski, Analysis of proinflammatory and antiinflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol 2011;136(5):696–704.
25. S.Uysal, F.Meriç Yilmaz, N.Boğdaycioğlu, Increased serum levels of some inflammatory markers in patients with multiple sclerosis. Minerva Medica 2014;105(3):229–35.
26. H.Bartosik-Psujek, Z.Stelmasiak. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005;12(1):49–54.
27. C.H.Polman, S.C.Reingold, G.Edan, Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–6.
28. F.D.Lublin, S.C.Reingold. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11.
29. J.F.Kurtzke Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444–52.
30. S.Rossi, V.Studer, C.Motta, Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflammation 2014. doi:10.1186/1742-2094-11-32.
31. J.Ziaber, J.Pasnik, Z.Baj, The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis. Mediat Inflamm 1998;7:335–8.
32. Y.Aoki, T.Miyatake, N.Shimizu, M.Yoshida. Medullasin activity in granulocytes of patients with multiple sclerosis. Ann Neurol 1984;15:245–9.
33. B.Guarnieri, F.Lolli, L.Amaducci. Polymorphonuclear neutral protease activity in multiple sclerosis and other diseases. Ann Neurol 1985;18:620–2.
34. J.H.Noseworthy, C.Luchinetti, M.Rodriguez, B.G.Weinshenker. Multiple sclerosis. N Engl J Med 2000;343:938–52.
35. B.G.W.Arnason, A.Dayal, Z.X.Qu, Mechanisms of action of interferon-β in multiple sclerosis. Semin Immunopathol 1996;18:125–48.
36. S.A.McMillan, G.V.McDonnell, J.P.Douglas, A.G.Droogan. Hawkins SA Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis. Neurology 1998;51:1156–60.
37. T.Ishizu, M.Osoegawa,, F.J.Mei,, Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128:988–1002.
38. J.Salzer, A.Svenningsson, P.Sundstrom. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287–92.
39. F.B.Aksungar, A.E.Topkaya, Z.Yildiz, Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J Clin Neurosci 2008;15(4):393–7.